Dr. Boris I. Medarov, MD

Dr. Medarov practices at Albany Medical College in Menands, New York.

Dr. Medarov's NPI, 1720055098, was assigned on March 4, 2006. Dr. Medarov graduated from Semmelweis University in 1997. Dr. Medarov holds California license A105076.

Dr. Medarov's primary practice is Albany Medical College, at 1275 Broadway, Menands, NY 12204 in Albany County. The practice phone is (518) 262-9600.

Dr. Medarov's primary practice is Albany Medical College in Menands, New York. Dr. Medarov is also affiliated with Albany Medical Center. The medical group on file is Albany Med EmUrgentCare. Dmand AI also links Dr. Medarov to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Medarov practices, 6 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Medarov's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dmand AI has Dr. Medarov's licenses on file in 2 states: California and Connecticut.

CMS data shows 651 Medicare services from Dr. Medarov across 14 procedure codes in 2024, for 416 Medicare patients. Medicare paid $87,978 for them.

CMS counts 416 Medicare patients who saw Dr. Medarov in 2024. The largest group is 65 to 74, with 183 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Medarov's median patient age at 56, with 49% women.

In 2024, Dr. Medarov wrote 1,109 Medicare Part D claims for 159 patients. 36% of them were for generic drugs. CMS names the drug for 928 of them, across 25 drugs with 11 or more claims each, at $4,031,775 in total drug cost. In 2023, CMS named 1,000 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Medarov for performance year 2024, reported as part of a group. Dr. Medarov accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 13 papers to Dr. Medarov, published from 2014 to 2022. 2021 was the busiest year, with 2. The most frequent topics are Hypertension, Pulmonary, COVID-19 and Dyspnea. Dr. Medarov has published most often in Respir Med. Dr. Medarov's most frequent co-authors are Woon Hean Chong, MD, Amit Chopra, MD and Lawrence Anh Tuan Ho, MD.

Dmand AI links Dr. Medarov to 7 clinical trials, 3 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Hypertension, Pulmonary, Pulmonary Arterial Hypertension and Hypertension. United Therapeutics sponsors the most, 5. Open Payments lists research payments to Dr. Medarov that name 1 trial.

CMS Open Payments shows 510 general payments to Dr. Medarov from 20 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 81% of the total. Actelion Pharmaceuticals US, Inc. paid the most, $122,677. It also lists 3 research payments totaling $2,590 in 2016, naming 1 clinical trial.

Dr. Medarov graduated from Semmelweis University in 1997.